Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can brain implants read and treat bipolar depression without triggering mania?

NCT ID NCT07745374

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study tests whether deep brain stimulation (DBS) can safely treat severe, treatment-resistant bipolar depression. The approach uses a brain implant that delivers stimulation and simultaneously monitors brain signals linked to depression and mania. The goal is to see if this real-time monitoring can guide therapy to ease depression while avoiding manic switches. The trial involves a small group of adults with bipolar I disorder who have been depressed for at least a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deep brain stimulation (DBS) using the Medtronic Percept PC system, with continuous monitoring of brain signals from the subcallosal cingulate and amygdala.
What this could lead to
If successful, this could lead to a personalized brain-stimulation therapy for severe bipolar depression that adjusts in real time to prevent manic episodes.
What could go wrong
This is a very small early-stage study (5 people), so results may not apply broadly. DBS is invasive brain surgery and carries risks like infection, bleeding, or mood changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 5 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 22-70 years * Ability to provide written informed consent * Primary diagnosis of Bipolar I Disorder confirmed by SCID-5 * Current major depressive episode (MDE) of at least 12 months duration * Stable control of mania for a minimum of 1 year * Agreement to remain on current anti-mania medication regimen * Hamilton Depression Rating Scale-17 (HDRS-17) score ≥20 at screening and baseline * Young Mania Rating Scale (YMRS) score \<12 at screening and baseline * Treatment-resistant depression: failure to respond to at least 4 adequate trials of antidepressant treatment in the current episode. Antidepressant treatments include: Medications (Must include 2 antidepressant medications from different pharmacological classes), Psychotherapy, ECT, repetitive transcranial magnetic stimulation (rTMS), IV ketamine or intra-nasal esketamine. * All patients must be receiving at least one mood stabilizing medication at entry into the trial. Medication regimen must be stable for a minimum of 4 weeks before the baseline visit. * Able to provide informed consent * English-speaking * Deemed suitable surgical candidate by neurosurgical evaluation * Under care of treating psychiatrist willing to collaborate with study team * Able to reside in New York Metropolitan area during first 6 months or willing/able to travel monthly to study site * Provision of at least two emergency contacts age ≥22 residing within reasonable proximity Exclusion Criteria * Current manic or hypomanic episode (YMRS ≥12) * Rapid cycling pattern (≥4 mood episodes in the past 12 months) * Active suicidal ideation with intent or plan * Suicide attempt within six months prior to baseline * Current psychotic symptoms * Primary diagnosis of schizophrenia, schizoaffective disorder, or other psychotic disorder * History (current and/or lifetime) of one or more schizophrenia-spectrum or other psychotic disorders including: schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, and major depressive disorder with psychosis (unipolar or bipolar), and/or psychotic depression (unipolar or bipolar) (does not include psychosis occurring in the context of a manic episode of a subject with bipolar disorder) * Substance use disorder (moderate or severe) within 6 months * Presence of any type of dementia / Major Neurocognitive Disorder / significant cognitive impairment interfering with study participation * Subject has had a prior VNS Therapy or deep brain stimulation (DBS) implant * Subject has a diagnosis of Substance Use Disorder as defined by the DSM-V without sustained remission (12 months or longer) * History of borderline or severe personality disorder, as determined by clinical judgment, which would significantly interfere with a subject's participation in the study * Active primary diagnosis of one or more of the following disorders: obsessive-compulsive disorder, eating disorder, or post-traumatic stress disorder * Cognitive or psychiatric deficit (e.g., amnesia, delirium) that in the investigator's judgment would interfere with the subject's ability to accurately complete study assessments * Current or lifetime history of psychotic features in any major depressive episode (MDE) * Treatment with another investigational device or investigational drugs * Contraindications to MRI (metallic implants, claustrophobia unmanageable with anxiolytics) * Contraindications to general anesthesia or neurosurgery * Significant structural brain abnormalities precluding safe electrode placement * Active infection or immunocompromised state * Active unstable medial condition (diabetes, heart disease, hypertension, cancer, endocrine) * BMI \>35; and/or CRP \>3 * Coagulopathy or anticoagulation that cannot be safely interrupted * Pregnancy or planning pregnancy during study period * Women of childbearing potential unwilling to use effective contraception * Prisoners or institutionalized individuals * Decisionally impaired individuals (unless previously consented when capacitated) * Special status patients (employees, VIPs, celebrities, public figures) unless consented before special status known

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Advanced Circuit Therapeutics, Clinical Neurosciences Center, Mount Sinai West

    RECRUITING

    New York, New York, 10019, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.